JAK3-IN-9 is an orally activeJAK3inhibitor withIC₅₀value of 1.7 nM. JAK3-IN-9 is highly selective to theJAK3signal path. JAK3-IN-9 is lowly toxic with high oral bioavailability, shows goodanti-arthritisactivity. JAK3-IN-9 can be used inautoimmunedisease research^[1].

JAK3-IN-9 (compound 11i) shows high selective inhibition of JAK3 withIC₅₀value of 1.7 nM^[1].

JAK3-IN-9 (compound 11i) (Female Lewis rats; 3, 10 and 30 mg/kg; Oral gavage once daily for 20 days) can selectively inhibit JAK3 cytokine signaling in the primary cells^[1].
JAK3-IN-9 (Male DBA1j of 8 to 12-weeks old mice; 1mg/kg, Intravenous injection, Single administration) shows high AUC of 2104 μg/ml, extends t_1/2to 2.56 h and good oral bioavailability of 48%^[1].
JAK3-IN-9 (30 mg/kg; Oral gavage once daily for 20 days) suppress paw swelling in a dose-dependent manner withED₅₀value of 10 mg/kg^[1].

393.46

C₁₇H₂₃N₅O₄S

1430095-30-9

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.